Myhre Syndrome Foundation’s Post

📣 Dear colleagues, Reviews in Cardiovascular Medicine is thrilled to announce a Call for Papers on the theme of “Tetralogy of Fallot”. Welcome to join the discussion! 📄 Sub-topic: (1) Advances in surgical techniques for Tetralogy of Fallot repair (2) Long-term outcomes and quality of life in Tetralogy of Fallot survivors (3) Novel imaging modalities for assessing Tetralogy of Fallot anatomy and function (4) Genetics and molecular mechanisms underlying Tetralogy of Fallot (5) Strategies for perioperative management and postoperative care (6) Emerging therapies and interventions for Tetralogy of Fallot patients About RCM: https://lnkd.in/gZhDbnDY For any questions: [email protected] #Cardiovascular #cardiac #openaccess #articles #TetralogyofFallot

Curious about the latest advancements in coronary physiology? Prof. Hans Reiber met Dr. Andrea Erriquez from Ferrara University Medical Center at EuroPCR this year. In this video, Dr. Erriquez shares intriguing insights from his groundbreaking QFiRe study, revealing compelling data that could redefine revascularization strategies. With the potential to shift how we approach non-culprit lesions, this conversation highlights the importance and benefits of QFR technology in interventional cardiology. But there's more to the story—Watch the full interview to discover what these findings could mean for your practice. You won’t want to miss the details of this pivotal research.

With such a rapid rate of advancement for pharmacologic therapies in cardiometabolic syndromes, conversations on the safety and efficacy of combination therapy have risen to the forefront of discussions. At #ESCCongress, we sat down with Brendon L Neuen, MBBS, PhD, of The George Institute for Global Health and Royal North Shore Hospital, to discuss a study he led examining the topic of combination GLP-1 RA and SGLT2 inhibitor use on cardiovascular and kidney outcomes in people with #Type2Diabetes using data from FLOW, Harmony Outcomes, and AMPLITUDE-O. https://lnkd.in/eX2_SXa3 #Cardiology #Nephrology

I'd like to bring attention to a recent paper published in Cell Reports Medicine (lead contact: Cunyi Fan, Shanghai Jiao Tong University). This paper looks at the mechanisms leading to neuroinflammation and peripheral nerve damage after brain injury. The authors find that Schwann cell-secreted frizzled-related protein 1 plays a critical role in mediating these changes. Check it out!

In a recent highlight from our webinar, "Unlocking Genetic Causes of Sudden Cardiac Death with Scalable Assays of Variant Effect," Dr. Victoria Parikh provided an insightful answer to an important question about utilizing assays of variant effects To hear Dr. Parikh's response and explore more about how scalable assays are transforming our approach to cardiac genetics, click the link to view the entire session. Don't miss these expert insights into advancing precision medicine in cardiology! Watch the Full Webinar Here: https://lnkd.in/d5BFGbn3 #CardiacGenetics #PrecisionMedicine #Webinar #MAVEvidence #ConstantiamBiosciences #polygenicconditions

After years of conversations where PGx (pharmacogenomics) was often described as “Star Wars stuff,” we’re finally witnessing the transition from futuristic to real-time clinical practice! 🚀 My father-in-law, a renowned cardiologist, Sergio Velasquez Rosas shared this moment from the 2024 European Society of Cardiology meeting, where personalized medicine in cardiology is making its way into clinical actionability. It’s exciting to see how far we’ve come in integrating genetic insights into everyday cardiology, moving closer to a future where treatments like clopidogrel are tailored not just based on one size fits all guidelines but including individual genetic profiles. #Pharmacogenomics #PersonalizedMedicine #Cardiology #ESC2024 #ClinicalInnovation #GenomicMedicine

Dr. Januzzi speaks about several advances on the horizon that will substantially change the landscape of how, when, and where biomarkers will be utilized in cardiology.  Watch the DeBakey Bytes video below to learn more https://lnkd.in/gTFzB-du, or click the link below for the full-length presentation. https://lnkd.in/gngkeGWQ

🚀 New Insights into Heart Failure: Unraveling the ACSL4-Ferroptosis Connection! 🫀 Exciting developments in the realm of cardiology! Researchers have discovered that an increase in phosphatidylethanolamines (PEs) and Acsl4 expression plays a pivotal role in heart failure. This new study highlights that overexpressing Acsl4 in cardiomyocytes worsens cardiac dysfunction via ferroptosis, but inhibition holds therapeutic promise. 🔍 Delving deeper, the research uncovers that Acsl4-dependent ferroptosis activates pyroptotic signaling, linked to inflammation in cardiac cells. By neutralizing the proinflammatory cytokine IL-1β, cardiac function was significantly improved in experimental models. This groundbreaking study offers hope. By targeting the ACSL4-ferroptosis-pyroptotic pathway, we might pave the way for innovative heart failure treatments. This could be a game-changer for many dealing with this challenging condition! 🏥✨ Read Research 👉🏻 https://lnkd.in/diQQVB4r #research #pubmed

In a recent highlight from our webinar, "Unlocking Genetic Causes of Sudden Cardiac Death with Scalable Assays of Variant Effect," Dr. Victoria Parikh provided an insightful answer to an important question about utilizing assays of variant effects To hear Dr. Parikh's response and explore more about how scalable assays are transforming our approach to cardiac genetics, click the link to view the entire session. Don't miss these expert insights into advancing precision medicine in cardiology! Watch the Full Webinar Here: https://lnkd.in/d5BFGbn3 hashtag #CardiacGenetics #PrecisionMedicine #Webinar #MAVEvidence #ConstantiamBiosciences

🔬Unlocking new frontiers in #CardiologyResearch! Our latest article in Exploration of Cardiology reveals groundbreaking findings: SGI-1027-loaded nanoparticles effectively reduce atherosclerosis in mice and curb inflammation in human macrophages.  A game-changer in epigenetic therapy!  🧬 #Atherosclerosis #Nanotechnology #Epigenetics" 🔗https://lnkd.in/gu9J2d-c